EUPRAXIA PHARMACEUTICALS INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
The yearly report of certain Canadian companies, filed under a joint US and Canadian system. It is the main yearly account these companies give US investors, largely as filed in Canada.
FY2024 · Filed Mar 20, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.4 — EX-99.4 CONSENT OF KPMG LLP
Exhibit 99.4
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Eupraxia Pharmaceuticals Inc.
We consent to the use of our report dated March 20, 2025 on the consolidated financial statements of Eupraxia Pharmaceuticals Inc. (the “Entity”) which comprise the consolidated balance sheets as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, changes in shareholders’ equity and cash flows for each of the years then ended, and the related notes (collectively the “consolidated financial statements”) which is included in the Annual Report on Form 40-F of the Entity for the fiscal year ended December 31, 2024.
We also consent to the incorporation by reference of such report in the Registration Statements (No. 333-276586) on Form F-10 and (No. 333-278534) on Form S-8 of the Entity.
/s/ KPMG LLP
Chartered Professional Accountants
March 20, 2025
Vancouver, Canada
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.